84407-13-6

Usage

Uses

Used in Pharmaceutical Industry:
2-(4-Amino-1H-pyrazol-1-yl)ethanol is used as a key intermediate in the synthesis of pyrazolo[1,5-a]pyrimidines, which are a class of compounds with CK2 kinase inhibitory activity. These pyrazolo pyrimidines have potential applications in the development of therapeutic agents for the treatment of various diseases, including cancer and inflammatory disorders.
Used in Chemical Research:
2-(4-Amino-1H-pyrazol-1-yl)ethanol is also utilized as a reagent in various chemical reactions, enabling the synthesis of novel compounds with potential applications in different fields, such as materials science, agrochemistry, and medicinal chemistry. Its unique structure and reactivity make it a valuable tool for researchers in the discovery and development of new chemical entities.

InChI:InChI=1/C5H9N3O/c6-5-3-7-8(4-5)1-2-9/h3-4,9H,1-2,6H2

Upstream product

• 109-84-2 2-hydroxyethylhydrazine 
• 107-14-2 chloroacetonitrile 
• 956951-01-2 2-(3-nitro-1H-pyrazol-1-yl)ethan-1-ol 
• 1003013-08-8 1-[2-(tert-butyl-dimethyl-silanyloxy)-ethyl]-3-nitro-1H-pyrazole 
• 920-37-6 2-Chloroacrylonitrile 

Downstream Products

• 1421856-72-5 C₁₈H₁₇FN₆O 

Relevant academic research and scientific papers

NEW 5,8-DIMETHYL-9-PHENYL-5,8-DIHYDRO-6H-PYRAZOLO[3,4-H]QUINAZOLIN-2- YL)-(1 H-PYRAZOL-3-YL)-AMINES AND DERIVATIVES AS IGF-1 R/IR INHIBITORS

The present invention encompasses compounds of formula (I) wherein the groups A, R and q are defined in claim 1, their use as inhibitors of IGF-1 R, pharmaceutical compositions which contain compounds of this kind and their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases.

Deacetylcolchicine deriv.

Provided are 4-modified colchicine compounds and medicines using the same. Specifically provided are colchicine derivatives represented by general formula (1), salts thereof, and solvates of the same. In general formula (1), R1 is a halogen atom, a hydroxyl group, a nitro group, an amino group, or a mono-, di- or tri-fluoromethyl group; R2, R3 and R4 are each a methoxy group or a hydroxyl group, or alternatively R2 and R3, or R3 and R4 together represent a methylenedioxy group; R5 and R6 may be the same or different and are each a hydrogen atom, a C1-6 alkyl group, an arylalkyl group, a C2-6 alkenyl group, -COR7, -COOR8, -SO2R9, -CONR10R11, or -CSNR12R13, or alternatively R5 and R6 together with the nitrogen atom to which R5 and R6 are bonded may form a three- to seven-membered cyclic amino group; R7 is a C1-6 alkyl group or the like; R8 is a C1-6 alkyl group or the like; R9 is a C1-6 alkyl group or the like; R10 and R11 may be the same or different and are each a hydrogen atom, a C1-6 alkyl group, or the like; and R12 and R13 may be the same or different and are each a hydrogen atom, an alkyl group, or the like.

PYRAZOLO[4,3-C]PYRIDINE DERIVATIVES AS JAK INHIBITORS

The present invention relates to compounds of formula (I) wherein X1 to X5, Y, Z1 to Z4, and R have the meaning as cited in the description and the claims. Said compounds are useful as JAK inhibitors for the tre

ISOINDOLINONE DERIVATIVES

The present invention relates to compounds of the formula I, as well as pharmaceutically-acceptable salts thereof, pharmaceutical compositions containing said compounds and methods of using said compounds in the treatment or prophylaxis of diseases and disorders. The compounds and compositions disclosed herein are glucokinase activators useful for the treatment or prophylaxis of metabolic diseases and disorders, for example diabetes mellitus, including type II diabetes mellitus.

HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS

The present invention relates to compounds of formula (I) wherein X1 to X5, Y, Z1 to Z3, and R have the meaning as cited in the description and the claims. Said compounds are useful as JAK inhibitors for the treatment or prophylaxis of immunological, inflammatory, autoimmune, allergic disorders, and immunologically-mediated diseases. The invention also relates to pharmaceutical compositions including said compounds, the preparation of such compounds as well as the use as medicaments.

INDAZOLE COMPOUNDS FOR ACTIVATING GLUCOKINASE

The present invention aims to provide a glucokinase activator useful as a pharmaceutical agent such as an agent for the prophylaxis or treatment of diabetes, obesity and the like. A compound represented by the formula (I): wherein R1, R2, R3, R4 are as defined herein; or a salt thereof.

AMIDE COMPOUNDS

A compound of the formula (I) wherein R1 is hydrogen, lower alkyl, lower alkenyl, halo(lower)alkyl, cyclo(lower)alkyl, lower alkoxy, lower alkylthio, acyl, optionally substituted aryl or NR3R4; R2 is hydrogen; or aryl or heteroaryl, each of which may be substituted; X is direct bond or bivalent residue derived from piperazine; Y is -(A1)n#191-(A2?)?m#191-, wherein n and m are independently 0 or 1); is bivalent residue derived from arene or heteroarene; and is bivalent residue derived from arene or heteroarene, or a salt thereof. The compound of the present invention and a salt thereof inhibit apolipoprotein B (Apo B) secretion and are useful as a medicament for prophylactic and treatment of diseases or conditions resulting from elevated circulating levels of Apo B.

HETEROCYCLIC DERIVATIVES

This invention relates to heterocyclic derivatives which are histamine H-2 antagonists and which inhibit gastric acid secretion. According to the invention there is provided a guanidine derivative of the formula I: STR1 in which R 1 and R 2, same or diffe

HALOALKYLGUANIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS, PROCESSES AND INTERMEDIATES

The invention relates to guanidine derivatives which are histamine H-2 antagonists and which inhibit gastric acid secretion. According to the invention there is provided a guanidine derivative of the formula I:-STR1 in which R 1 and R 2, same or different, are hydrogen or 1-10C alkyl, 3-8C cycloalkyl or 4-14C cycloalkylalkyl, each alkyl, cycloalkyl or cycloalkylalkyl optionally carrying one or more F, Cl or Br atoms, provided that one of R 1 and R 2 is halogen substituted, or R 2 is hydrogen and R 1 is R 5--E--W in which W is 2-6C alkylene optionally substituted by 1 or 2 1-4C alkyls, E is O,S or NR 6 in which R 6 is H or 1-6C alkyl, R 5 is H or 1-6C alkyl optionally substituted by 1 or 2 1-4C alkyls, or R 5 and R. sup.6 are joined to form a pyrrolidine, piperidine, morpholine, piperazine or N-methylpiperazine ring; ring X is a heterocyclic ring as defined in the specification; A is phenylene or 5-7C cycloalkylene, or a 1-8C alkylene into which is optionally inserted one or two groups; D is O or S; and R. sup.3 and R 4 are hydrogen or a variety of radicals described in the specification: and the pharmaceutically-acceptable acid-addition salts thereof. Manufacturing processes and pharmaceutical compositions are also described.